Accepted Manuscripts
Back to the articles list |
Back to browse issues page
Fatemeh Taghizadeh 
, Farzaneh Rezaei Yazdi , Parinaz Javanbakht , Sobhan Ghazanfari Moghadam , Davood Zarini , Sina Mojaverrostami
, Farzaneh Rezaei Yazdi , Parinaz Javanbakht , Sobhan Ghazanfari Moghadam , Davood Zarini , Sina Mojaverrostami
Abstract: (10 Views)
Multiple sclerosis (MS) is a complex disorder characterized by inflammation and neurodegeneration within the central nervous system (CNS). Resveratrol (RES) is a naturally occurring polyphenolic compound with broad antioxidant and anti‑inflammatory properties. As the most common demyelinating disease of the CNS, MS is defined by perivascular inflammation, demyelination, and axonal loss. This review aims to systematically evaluate the preclinical evidence for RES in MS models, elucidate its molecular mechanisms, and identify gaps that limit clinical translation. Preclinical investigations consistently demonstrate the beneficial impact of RES in animal models of MS through its remyelinating, anti‑inflammatory, and antioxidant activities, as well as its protective effects on the blood brain barrier. RES, in addition to the aforementioned effects, has also been shown in pre‑clinical studies to improve MS through mechanisms such as SIRT1 activation, T‑cell apoptosis, modulation of the miR‑124/SK1 axis, and enhancement of autophagy. Although RES exhibits several promising therapeutic properties, confirmation through robust clinical trials is essential before recommending RES as a treatment option for patients with MS.
Multiple sclerosis (MS) is a complex disorder characterized by inflammation and neurodegeneration within the central nervous system (CNS). Resveratrol (RES) is a naturally occurring polyphenolic compound with broad antioxidant and anti‑inflammatory properties. As the most common demyelinating disease of the CNS, MS is defined by perivascular inflammation, demyelination, and axonal loss. This review aims to systematically evaluate the preclinical evidence for RES in MS models, elucidate its molecular mechanisms, and identify gaps that limit clinical translation. Preclinical investigations consistently demonstrate the beneficial impact of RES in animal models of MS through its remyelinating, anti‑inflammatory, and antioxidant activities, as well as its protective effects on the blood brain barrier. RES, in addition to the aforementioned effects, has also been shown in pre‑clinical studies to improve MS through mechanisms such as SIRT1 activation, T‑cell apoptosis, modulation of the miR‑124/SK1 axis, and enhancement of autophagy. Although RES exhibits several promising therapeutic properties, confirmation through robust clinical trials is essential before recommending RES as a treatment option for patients with MS.
Multiple sclerosis (MS) is a complex disorder characterized by inflammation and neurodegeneration within the central nervous system (CNS). Resveratrol (RES) is a naturally occurring polyphenolic compound with broad antioxidant and anti‑inflammatory properties. As the most common demyelinating disease of the CNS, MS is defined by perivascular inflammation, demyelination, and axonal loss. This review aims to systematically evaluate the preclinical evidence for RES in MS models, elucidate its molecular mechanisms, and identify gaps that limit clinical translation. Preclinical investigations consistently demonstrate the beneficial impact of RES in animal models of MS through its remyelinating, anti‑inflammatory, and antioxidant activities, as well as its protective effects on the blood brain barrier. RES, in addition to the aforementioned effects, has also been shown in pre‑clinical studies to improve MS through mechanisms such as SIRT1 activation, T‑cell apoptosis, modulation of the miR‑124/SK1 axis, and enhancement of autophagy. Although RES exhibits several promising therapeutic properties, confirmation through robust clinical trials is essential before recommending RES as a treatment option for patients with MS.
Type of Manuscript: Review |
Subject:
Neurophysiology/Pharmacology
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
